Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The global prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia infections, particularly in children, is on the rise. It is imperative to assess the clinical efficacies of alternative antibiotics such as tetracyclines to ensure effective treatment, mitigate antibiotic resistance, enhance clinical outcomes, and minimize the spread of resistant strains among MRMP-infected children. The objective of this study was to compare the therapeutic efficacies of macrolides and tetracyclines in treating MRMP pneumonia in children.
Methods: We systematically searched the literature to identify comparative studies that examined the clinical outcomes of macrolide and tetracycline antibiotics in children with MRMP pneumonia. We conducted a meta-analysis of the mean duration of fever, hospital stay duration, therapeutic efficacies, and time to defervescence to compare macrolides and tetracyclines.
Results: Eleven studies involving 1143 patients compared the clinical efficacies of macrolides and tetracyclines in children with MRMP pneumonia. The studies were conducted in China, Japan, and Korea, and the outcomes of febrile days, hospital stay duration, therapeutic efficacy, and time to defervescence were analyzed. The macrolides studied were azithromycin and clarithromycin, whereas the tetracyclines included minocycline and doxycycline. The pooled estimate of 5 studies showed that the mean duration of febrile days and hospital stay was longer in the macrolides group than tetracycline group [weighted mean difference = 1.64 days, 95% confidence interval (CI): 0.68-2.59, weighted mean difference = 1.22 days, 95% CI: 0.82-1.62, respectively]. The therapeutic efficacy was significantly lower in the macrolide group than in the tetracycline group (odds ratio: 0.33, 95% CI: 0.20-0.57).
Conclusions: The clinical efficacy of tetracycline treatment was superior to that of macrolide treatment in children with MRMP pneumonia. However, further research is required to validate these findings and inform evidence-based clinical practice guidelines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/INF.0000000000004568 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Etiological characteristics of Mycoplasma pneumoniae infection and macrolide resistance in children in beijing: a retrospective study from 2018 to 2024.
Eur J Clin Microbiol Infect Dis
August 2025
Laboratory of Respiratory Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Core Technologies for the Prevention and Treatment of Emerging Infectious Diseases in Children, Key Laboratory of Major Diseases in Children, M
Background: Mycoplasma pneumoniae (MP) is a major cause of pediatric respiratory tract infections (RTIs), with recent increases in incidence and macrolide resistance. The epidemiology of MP, macrolide-resistant MP (MRMP), co-infection patterns, and their relationship with disease severity in the post-COVID era remain poorly understood. We analyzed temporal trends in MP infection and MRMP prevalence and assessed their association with severe community-acquired pneumonia (SCAP).
View Article and Find Full Text PDFRespiratory microbiome and metabolome features associate disease severity and the need for doxycycline treatment in children with macrolide-resistant -mediated pneumonia.
Front Cell Infect Microbiol
August 2025
Department of Pediatrics, Chang Gung Children's Hospital, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taoyuan, Taiwan.
Introduction: Commensal bacterial community along the upper respiratory tract functions against pathogens. The host determinants of severity should be identified against the increasing threat of macrolide-resistant (MRMP) infection. We hypothesized that respiratory microbiome is involved in the clinical manifestations of infection.
View Article and Find Full Text PDFAdvances in adhesion-related pathogenesis in infection.
Front Microbiol
July 2025
Department of Pediatric Respiration, Children's Medical Center, The First Hospital of Jilin University, Changchun, China.
is a leading cause of community-acquired pneumonia (CAP) and upper respiratory tract infections, particularly in children and immunocompromised individuals. The growing global prevalence of macrolide-resistant (MRMP) further emphasizes the urgent need to elucidate its pathogenic mechanisms. Among these, adhesion plays a central role, serving as a prerequisite for colonization and disease progression, and thus warrants detailed investigation.
View Article and Find Full Text PDFQuestion: A 5-year-old child was seen in our clinic with a clinical presentation consistent with community-acquired pneumonia. She was prescribed a course of amoxicillin and azithromycin, but remained febrile and returned to the clinic 3 days later. The family just returned from a trip to Japan.
View Article and Find Full Text PDFClinical features and risk factors for severe macrolide-resistant mycoplasma pneumoniae pneumonia induced by 23 S rRNA A2063G mutation: a retrospective observational study.
Eur J Clin Microbiol Infect Dis
July 2025
Department of Infectious Disease, Yunnan Key Specialty of Pediatric Infection (Training and Education Program), Kunming Key Specialty of Pediatric Infection, Kunming Children's Hospital, Kunming, 650000, Yunnan, China.
Objectives: This study aimed to investigate the clinical characteristics and risk factors of severe macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMP) induced by the 23 S rRNA A2063G mutation.
Methods: Clinical data were collected from 526 pediatric patients diagnosed with Mycoplasma pneumoniae pneumonia (MPP) at Kunming Children's Hospital, representing a single-center cohort study conducted between October 2023 and February 2024. Among them, 483 cases (91.